A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.

作者： Scott McCallister , Hernan Valdez , Kevin Curry , Thomas MacGregor , Marie Borin

DOI: 10.1097/00126334-200404010-00007

关键词:

摘要: … A protocol for evaluation of the antiviral efficacy of antiretrovirals in a 14-day monotherapy … plasma TPV concentrations equivalent to those obtained after administration of two 300-mg …

参考文章(11)

S M Poppe, D E Slade, K T Chong, R R Hinshaw, P J Pagano, M Markowitz, D D Ho, H Mo, R R Gorman, T J Dueweke, S Thaisrivongs, W G Tarpley, Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 1058- 1063 ,(1997) , 10.1128/AAC.41.5.1058

Brendan A Larder, Kurt Hertogs, Stuart Bloor, Ch. van den Eynde, Wanda DeCian, Yenyun Wang, William W Freimuth, Gary Tarpley, Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS. ,vol. 14, pp. 1943- 1948 ,(2000) , 10.1097/00002030-200009080-00009

Suvit Thaisrivongs, Joseph W. Strohbach, Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers. ,vol. 51, pp. 51- 58 ,(1999) , 10.1002/(SICI)1097-0282(1999)51:1<51::AID-BIP6>3.0.CO;2-U

Nicole K.T. Back, Albert van Wijk, DaniMlle Remmerswaal, Marion van Monfort, Monique Nijhuis, Rob Schuurman, Charles A.B. Boucher, In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS. ,vol. 14, pp. 101- 102 ,(2000) , 10.1097/00002030-200001070-00019

Stefano Rusconi, Simona La Seta Catamancio, Paola Citterio, Semir Kurtagic, Michela Violin, Claudia Balotta, Mauro Moroni, Massimo Galli, Antonella d'Arminio-Monforte, Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors Antimicrobial Agents and Chemotherapy. ,vol. 44, pp. 1328- 1332 ,(2000) , 10.1128/AAC.44.5.1328-1332.2000

David D. Ho, Avidan U. Neumann, Alan S. Perelson, Wen Chen, John M. Leonard, Martin Markowitz, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature. ,vol. 373, pp. 123- 126 ,(1995) , 10.1038/373123A0

Suvit Thaisrivongs, Harvey I. Skulnick, Steve R. Turner, Joseph W. Strohbach, Ruben A. Tommasi, Paul D. Johnson, Paul A. Aristoff, Thomas M. Judge, Ronald B. Gammill, Jeanette K. Morris, Karen R. Romines, Robert A. Chrusciel, Roger R. Hinshaw, Kong-Teck Chong, W. Gary Tarpley, Susan M. Poppe, David E. Slade, Janet C. Lynn, Miao-Miao Horng, Paul K. Tomich, Eric P. Seest, Lester A. Dolak, W. Jeffrey Howe, Gina M. Howard, Francis J. Schwende, Lisa N. Toth, Guy E. Padbury, Grace J. Wilson, Lihua Shiou, Gail L. Zipp, Karen F. Wilkinson, Bob D. Rush, Mary J. Ruwart, Kenneth A. Koeplinger, Zhiyang Zhao, Serena Cole, Renee M. Zaya, Thomas J. Kakuk, Musiri N. Janakiraman, Keith D. Watenpaugh, Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. Journal of Medicinal Chemistry. ,vol. 39, pp. 4349- 4353 ,(1996) , 10.1021/JM960541S

GJ Moyle, D Back, Principles and practice of HIV-protease inhibitor pharmacoenhancement. Hiv Medicine. ,vol. 2, pp. 105- 113 ,(2001) , 10.1046/J.1468-1293.2001.00063.X

Robert L. Murphy, Scott Brun, Charles Hicks, Joseph J. Eron, Roy Gulick, Martin King, A. Clinton White, Constance Benson, Melanie Thompson, Harold A. Kessler, Scott Hammer, Richard Bertz, Ann Hsu, Anthony Japour, Eugene Sun, ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. ,vol. 15, ,(2001) , 10.1097/00002030-200101050-00002

10.

Steve R. Turner, Joseph W. Strohbach, Ruben A. Tommasi, Paul A. Aristoff, Paul D. Johnson, Harvey I. Skulnick, Lester A. Dolak, Eric P. Seest, Paul K. Tomich, Michael J. Bohanon, Miao-Miao Horng, Janet C. Lynn, Kong-Teck Chong, Roger R. Hinshaw, Keith D. Watenpaugh, Musiri N. Janakiraman, Suvit Thaisrivongs, Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇ Journal of Medicinal Chemistry. ,vol. 41, pp. 3467- 3476 ,(1998) , 10.1021/JM9802158

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.

来源期刊

我的账户

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.

来源期刊

相似文章 10

我的账户